Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Protara Therapeutics Inc

Healthcare US TARA

4.04USD
-0.12(2.88%)

Last update at 2026-06-08T20:00:00Z

Day Range

4.004.30
LowHigh

52 Week Range

1.045.24
LowHigh

Fundamentals

  • Previous Close 4.16
  • Market Cap57.45M
  • Volume723062
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-45.38500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -65.95200M -47.25200M -33.97800M -14.99200M -25.43700M
Minority interest - - - - -
Net income -64.81500M -47.13500M -33.51200M -14.73000M -25.43700M
Selling general administrative 20.74M 26.40M 22.46M 8.82M 10.57M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.25M 0.12M 0.20M 0.28M 0.12M
Ebit -67.06200M -47.48900M -34.44400M -15.25400M -26.51600M
Ebitda -8.02800M -47.25200M -34.24800M -15.23700M -26.40100M
Depreciation and amortization 59.03M 0.24M 0.20M 0.02M 0.12M
Non operating income net other - - - 0.26M 0.64M
Operating income -67.06200M -47.48900M -34.44400M -15.25400M -26.08000M
Other operating expenses 37.55M 47.49M 34.44M 15.25M 26.08M
Interest expense 1.14M 1.74M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 2.23M 1.97M - 0.26M 0.44M
Net interest income 1.09M 0.24M 0.47M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.13700M -0.11700M -0.46600M -0.26200M 5.35M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 37.55M 47.49M 34.44M 15.25M 26.08M
Cost of revenue - - - - -
Total other income expense net 1.11M 0.24M 0.47M 0.26M 0.64M
Discontinued operations - - - - -
Net income from continuing ops -65.95200M -47.25200M -33.97800M -14.99200M -20.72900M
Net income applicable to common shares -65.95200M -47.25200M -33.97800M -14.99200M -20.72900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 78.95M 113.29M 172.60M 203.16M 6.97M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.88M 0.13M 0.03M 0.79M 0.74M
Total liab 10.63M 11.21M 10.68M 3.91M 0.58M
Total stockholder equity 68.32M 102.08M 161.91M 199.24M 6.39M
Deferred long term liab - - - - -
Other current liab 2.73M 3.24M 2.49M 1.91M 0.32M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00300M
Capital stock 0.01M 0.01M 0.01M 0.01M 18.46M
Retained earnings -200.38400M -159.96400M -94.01200M -46.76000M -225.46200M
Other liab - - - - -
Good will - 0.00000M 29.52M 29.52M -
Other assets 0.00000M 1.39M 1.61M 1.91M -
Cash 39.59M 24.13M 35.72M 168.60M 6.18M
Cash and equivalents - - - - -
Total current liabilities 6.15M 5.74M 4.30M 2.92M 0.58M
Current deferred revenue - - - - -
Net debt -34.11900M -17.74300M -28.48500M -167.51100M -6.18100M
Short term debt 0.98M 0.92M 0.85M 0.09M -
Short long term debt - - - - -
Short long term debt total 5.47M 6.38M 7.24M 1.09M -
Other stockholder equity 268.73M 262.72M 256.13M 245.99M 213.39M
Property plant equipment - 7.87M 8.89M 1.24M 0.46M
Total current assets 68.70M 86.15M 93.11M 169.44M 6.97M
Long term investments 0.00000M 17.89M 39.47M 0.74M -
Net tangible assets - 102.08M 132.40M 169.73M -12.07100M
Short term investments 25.99M 60.24M 55.51M - 0.00000M
Net receivables 0.24M 0.49M 0.63M - -
Long term debt - - - - -
Inventory - 1.16M 1.22M - -
Accounts payable 2.43M 1.59M 0.95M 0.91M 0.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.03100M -0.68800M -0.21100M - 0.00300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.01M -
Preferred stock total equity - - - - 18.46M
Retained earnings total equity - - - -46.76000M -225.46200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.94M 1.39M 1.61M 2.96M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 10.25M 27.14M 79.48M 33.72M 0.00000M
Capital lease obligations 5.47M 6.38M 7.24M 1.09M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 14.95M -97.59800M 2.83M 2.50M 18.55M
Change to liabilities 0.63M 0.04M -0.76800M -2.49700M -6.16200M
Total cashflows from investing activities 14.95M -98.19400M 2.83M 2.48M 18.43M
Net borrowings - - -1.66900M -1.66900M -1.66900M
Total cash from financing activities -0.09000M -0.22800M 189.40M 0.50M 2.98M
Change to operating activities -0.09200M -0.55600M 0.43M 2.01M 0.39M
Net income -65.95200M -47.25200M -33.97800M -14.99200M -20.72900M
Change in cash -11.59700M -132.92400M 168.83M -13.16200M -1.79900M
Begin period cash flow 36.47M 169.39M 0.56M 19.39M 21.19M
End period cash flow 24.87M 36.47M 169.39M 6.23M 19.39M
Total cash from operating activities -26.45700M -34.50200M -23.40700M -15.64600M -23.23300M
Issuance of capital stock - 0.00000M 179.45M 0.00000M 2.85M
Depreciation 0.25M 0.12M 0.20M 0.28M 0.12M
Other cashflows from investing activities - - 3.72M 2.50M 18.55M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.02M 0.05M
Sale purchase of stock -0.09000M -0.22800M 94.00M - 2.98M
Other cashflows from financing activities 14.95M -98.19400M 103.22M 2.48M 0.13M
Change to netincome 38.71M 12.10M 9.75M 0.94M 3.40M
Capital expenditures 0.12M 0.60M 0.88M 0.02M 0.12M
Change receivables - - - 0.02M 0.05M
Cash flows other operating - - 1.49M 0.61M 0.14M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 168.83M -13.16200M -1.82100M
Change in working capital 0.54M 0.53M 0.63M -1.87200M -5.97200M
Stock based compensation 6.69M 10.36M 9.75M 0.94M 3.43M
Other non cash items 32.02M 1.74M -159.49900M -0.00400M -0.07600M
Free cash flow -26.57700M -35.09800M -24.29100M -15.66200M -23.35200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TARA
Protara Therapeutics Inc		 -0.12 2.88% 4.04 - - - 0.51 0.59
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Protara Therapeutics Inc

345 Park Avenue South, New York, NY, United States, 10010

Key Executives

Name Title Year Born
Mr. Jesse Shefferman Co-Founder, Principal Financial Officer, CEO, Pres & Director 1972
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Sr. VP & Chief Scientific Operations Officer 1981
Ms. Hannah Fry Principal Accounting Officer & Controller 1990
Ms. Justine O'Malley Sr. VP of Investor Relations & Corp. Affairs NA
Ms. Mary J. Grendell Gen. Counsel & Corp. Sec. NA
Ms. Kristine Rosse Sr. VP & Chief People Officer NA
Dr. Jathin Bandari M.D. Chief Medical Officer NA
Mr. Jesse Shefferman Co-Founder, CEO, President & Director 1972
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Senior VP & Chief Scientific Operations Officer 1981
Dr. Jathin Bandari M.D. Executive Officer 1988

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.